Cargando…
Brain-derived neurotrophic factor and schizophrenia
Schizophrenia is a severe disorder affecting approximately 1% of the population. Historically, alterations of dopaminergic function were considered the primary cause of schizophrenia. However, for many patients, drugs that alter dopaminergic function do not consistently lead to resolution of the sym...
Autor principal: | Gören, Jessica L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
College of Psychiatric & Neurologic Pharmacists
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007539/ https://www.ncbi.nlm.nih.gov/pubmed/29955483 http://dx.doi.org/10.9740/mhc.2016.11.285 |
Ejemplares similares
-
Glycinergic signaling in the human nervous system: An overview of therapeutic drug targets and clinical effects
por: Schmidt, Robert W., et al.
Publicado: (2016) -
Delta-9-tetrahydrocannabinol and cannabidiol: Separating the chemicals from the “weed,” a pharmacodynamic discussion
por: Boggs, Douglas Lee, et al.
Publicado: (2016) -
Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients
por: Misiak, Błażej, et al.
Publicado: (2014) -
Bilastine vs. hydroxyzine: occupation of brain histamine H(1)-receptors evaluated by positron emission tomography in healthy volunteers
por: Farré, Magí, et al.
Publicado: (2014) -
Potential cardiovascular adverse events when phenylephrine is combined with paracetamol: simulation and narrative review
por: Atkinson, Hartley C., et al.
Publicado: (2015)